Custom CRISPR Multiplex sgRNA Vectors
Interested in knocking out multiple genes or recruiting transcriptional regulators using a combination of sgRNAs? abm’s CRISPR multiplex gRNA system allows for optimal expression of multiple gRNAs from alternating U6 and H1 RNA pol III promoters on a single lentiviral vector. gRNAs may be designed for use with any Cas9 variant, which is expressed from a separate vector (click here to see abm’s full list of Cas9-expressing vectors and viruses). Just tell us what you want to accomplish, and we’ll do the sgRNA design, cloning, and lentiviral packaging for you.
|sgRNA Service (for spCas9)||No. of sgRNAs||Quantity||Cat. No.||Price|
|Custom CRISPR Dual sgRNA Lentivector (for spCas9)||2||1.0 ug||C420||$395.00|
|Custom CRISPR Triple sgRNA Lentivector (for spCas9)||3||1.0 ug||C421||$595.00|
|Custom CRISPR Quad sgRNA Lentivector (for spCas9)||4||1.0 ug||C422||$795.00|
|Custom CRISPR Multiplex sgRNA Lentivector (for spCas9)||>4||1.0 ug||C423||Inquire|
|sgRNA Service (for saCas9)||No. of sgRNAs||Quantity||CAT. NO.||PRICE|
|Custom CRISPR Dual sgRNA Lentivector (for saCas9)||2||1.0 ug||C511||$395.00|
|Custom CRISPR Triple sgRNA Lentivector (for saCas9)||3||1.0 ug||C512||$595.00|
|Custom CRISPR Quad sgRNA Lentivector (for saCas9)||4||1.0 ug||C513||$795.00|
|Custom CRISPR Multiplex sgRNA Lentivector (for saCas9)||>4||1.0 ug||C514||Inquire|
|Packaging Options||Volume||CAT. NO.||PRICE|
|Custom Recombinant Lentivirus (106 IU/ml)||10 ml||LV002||$650.00|
|High Titer Custom Recombinant Lentivirus (107 IU/ml)||1.0 ml||LV002-a||$850.00|
|High Titer Custom Recombinant Lentivirus (108 IU/ml)||550 ul||LV002-b||$1100.00|
|High Titer Custom Recombinant Lentivirus (109 IU/ml)||100 ul||LV002-c||$1350.00|
|High Titer Custom Recombinant Lentivirus (1010 IU/ml)||100 ul||LV002-d||$1850.00|
Multi-target genomic mutagenesis:
- Target multiple sites at a single locus or target multiple different loci simultaneously
- Convenient for use with Cas9 nickase to increase specificity and reduce off-target effects. Easily co-express multiple gRNAs simultaneously.
- sgRNAs can be designed for use with any Cas9 (saCas9, spCas9, dCas9-SAM, dCas9-KRAB, etc.)
Simultaneous activation, repression, knockout of multiple genomic targets:
- Activation using dCas9-SAM
- Repression using dCas9-KRAB
- Knockout using spCas9 or saCas9
|What promoter(s) do your sgRNA and All-in-One lentivectors have?|
sgRNAs are expressed from the U6 promoter and All-in-One lentivectors and lentiviruses express Cas9 from the SFFV promoter.
|What is the approximate time frame to generate CRISPR lentiviral constructs?|
The typical lead time is around 1-3 weeks for CRISPR lentivectors and 4-6 weeks for lentiviruses. Please inquire for a more accurate lead time.
|How should I store my lentivirus?|
Aliquots should be made for the lentivirus and stored at -70 degrees Celsius.
|If a high-titer custom lentivirus was ordered, do you do the lentiviral titration after a freeze-thaw or straight after production before the freeze-down step?|
We do the titration after aliquoting and freeze-down. Thus, the titer should be accurate for the customer after they thaw the finished product for the first time.
|Which virus has your lentivirus expression system been derived from? Is it HIV?|
Our lentivirus expression system is derived from Human HIV-1 Virus. It employs third generation self-inactivating recombinant lentiviral vectors with enhanced biosafety features and minimal relation to wild-type Human HIV-1 Virus.
|How do you verify the titer?|
We use our LV900 series - qPCR Lentivirus Titration(Titer) Kit. This kit quantifies a proprietary region of the lentiviral 5’-LTR.
|What is the packaging capacity for Lentivirus?|
The maximum insert size is <9 kb between the 5'LTR to 3'LTR.
|01||Kang, Y. J. et al. "Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling." Nat. Commun. (2015) 6:8371 doi: 10.1038/ncomms9371|
|02||Jiang, G. et al. "Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis." Cancer Prev Res. Published Online First April 14, 2016.doi: 10.1158/1940-6207.CAPR-15-0338|
|03||Okugawa, Y. et al. "Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer." Gut (2015)doi:10.1136/gutjnl-2015-309359|